Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Fintel on MSN5d
Leerink Partners Upgrades Genmab A (GMAB)
Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Yahoo Finance5d
Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Share Repurchase Plan: Approximately $370 million in 2025. Genmab AS (NASDAQ:GMAB) achieved a 31% total revenue growth in 2024, driven by the success of its eight commercialized medicines ...
Q3 Earnings Forecast for Genmab A/S Issued By William Blair
Equities researchers at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a research note issued on Thursday, February 13th. William Blair analyst M. Phipps forecasts ...
TD Cowen Keeps Their Hold Rating on Genmab (GMAB)
In a report released today, Yaron Werber from TD Cowen maintained a Hold rating on Genmab (GMAB – Research Report). The company’s shares closed ...